Karaciğer Nakilli Bir Hastada İlaç İlişkili Aneminin Muhtemel Sebebi Olarak Tenofovir Disoproksil Fumarat

Öz

Tenofovir disoproxil fumarat kronik hepatit B tedavisinde kullanılan etki gücü yüksek yan etki potansiyeli düşük bir antiviral ajandır. Hepatit B’ye bağlı karaciğer sirozu nedeniyle karaciğer nakli yapılan hastalarda nakil sonrası rekürrensin önlenmesi amacıyla da kullanılmaktadır. Bu yazıda hepatit B proflaksisi için adefovir kullanmaktayken tedavisi tenofovir disoproksil fumarata değiştirilen ve sonrasında ilaç ilişkili hemolitik anemi geliştiği düşünülen karaciğer nakilli bir hasta bildirilmiştir

Anahtar Kelimeler

• Tenofovir disoproksil fumarat, Anemi, Kronik hepatit B, Karaciğer nakli

Tenofovir Disoproxil Fumarate as a Possible Agent of Drug-Induced Anemia in a Liver Transplant Patient

Abstract

Tenofovir disoproxil fumarate is an antiviral agent with high potency and low side effect profile. It is also used for the prevention of recurrence in patients undergoing liver transplantation due to liver cirrhosis secondary to hepatitis B. In this article, we report a patient with liver transplantation who had been treated with adefovir for hepatitis B prophylaxis and whose treatment was changed to tenofovir disoproxil fumarate, and was then thought to develop drug-induced hemolytic anemia

Keywords

• Tenofovir disoproxil fumarate, Anemia, Chronic hepatitis B, Liver transplantation

Kaynakça

1. Maiwall R, Kumar M. Prevention and treatment of recurrent hepatitis B after liver transplantation. J Clin Transl Hepatol 2016; 4(1):54-65.
2. Xi ZF, Xia Q. Recent advances in prevention of hepatitis B recurrence after liver transplantation. World J Gastroenterol 2015; 21(3):829-35.
3. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23):2442-55.
4. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5):227-41.
5. Parkes-Ratanshi R, Katende D, Levin J, Wakeham K, Heiner G, Kamali A, Lalloo DG. Development of severe anaemia and changes in Haemoglobin (Hb) in a cohort of HIV infected Ugandan Adults receiving Zidovudine, Stavudine and Tenofovir containing antiretroviral regimens. J Int Assoc Provid AIDS Care 2015; 14(5):455- 62.
6. Kunimoto Y, Ikeda H, Fujii S, Kitagawa M, Yamazaki K, Nakata H, Noda N, Ishida T, Miyamoto A. Plasma tenofovir trough concentrations are associated with renal dysfunction in Japanese patients with HIV infection: A retrospective cohort study. J Pharm Health Care Sci 2016; 2:22.